Chargement en cours...
EXTH-76. (1)H AND HYPERPOLARIZED (13)C MRS BIOMARKERS OF IDH1 MUTANT GLIOMA RESPONSE TO TEMOZOLOMIDE THERAPY
The alkylating agent temozolomide (TMZ), previously reserved for treatment of glioblastoma, is now being considered for the treatment of low-grade glioma that are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene. Though the treatment of IDH1 mutant patients with TMZ improves surviva...
Enregistré dans:
| Publié dans: | Neuro Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216354/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.423 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|